Skip to content
sellWeak cluster of 2

Kevin Feeley sold $438k of WGS

CHIEF FINANCIAL OFFICER at GeneDx Holdings Corp.. 5,706 shares at an average of $76.80, traded Mar 16, 2026, filed Mar 17, 2026.

Warning score
37
Value
$438k
5,706 shares
Holdings after
27,148
-17% from before
From 52-week low
+35%
low $56.36, close $76.11
From 52-week high
-55%
high $167.51, as of Mar 16, 2026

Score components

  • Role
    CFO
    +22
  • Trade size
    $438k at market
    +17
  • Share of holdings sold
    Sold 17% of holdings
    +5
  • Cluster
    2 insiders selling within 14 days
    +8
  • Exercise and sell
    Shares came from an option exercise in the same filing
    -15

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

WGSOct 9, 2026 · close 67.33
Since filing Mar 17, 2026: -10.8%SPY +17.0% · excess -27.8%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001944119-26-000019, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Mar 15, 2026MOption exercise
Class A Common Stock
+3,815$0.00$025,657Mar 17, 2026
Mar 16, 2026MOption exercise
Class A Common Stock
+7,197$0.00$032,854Mar 17, 2026
Mar 16, 2026SOpen-market sale
Class A Common Stock
-2,384$76.35$182k30,470Mar 17, 2026
Mar 16, 2026SOpen-market sale
Class A Common Stock
-3,065$77.05$236k27,405Mar 17, 2026
Mar 16, 2026SOpen-market sale
Class A Common Stock
-257$77.94$20k27,148Mar 17, 2026
Mar 15, 2026MOption exercise
Restricted Stock Unitderivative
-3,815$0.00$011,446Mar 17, 2026
Mar 16, 2026MOption exercise
Restricted Stock Unitderivative
-7,197$0.00$028,787Mar 17, 2026

Related signals

Other insiders at GeneDx Holdings Corp. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
30Weak
WGSsell 2
GeneDx Holdings Corp.
Kevin Feeley
CHIEF FINANCIAL OFFICER
$364k
3,728 shares
-8%
43Moderate
WGSsell 2
GeneDx Holdings Corp.
Katherine Stueland
CHIEF EXECUTIVE OFFICER
$1.0M
10,501 shares
-8%
25Weak
WGSsell 2
GeneDx Holdings Corp.
Kevin Feeley
CHIEF FINANCIAL OFFICER
$108k
1,285 shares
-3%
32Weak
WGSsell 2
GeneDx Holdings Corp.
Katherine Stueland
CHIEF EXECUTIVE OFFICER
$311k
3,692 shares
-3%
20Weak
WGSsell 2
GeneDx Holdings Corp.
Kevin Feeley
CHIEF FINANCIAL OFFICER
$31k
372 shares
-1%
39Weak
WGSsell 2
GeneDx Holdings Corp.
Kevin Feeley
CHIEF FINANCIAL OFFICER
$557k
8,818 shares
-20%
53Moderate
WGSsell 2
GeneDx Holdings Corp.
Katherine Stueland
CHIEF EXECUTIVE OFFICER
$3.0M
46,933 shares
-34%
48Moderate
WGSsell 2
GeneDx Holdings Corp.
Katherine Stueland
CHIEF EXECUTIVE OFFICER
$1.3M
17,179 shares
-23%
25Weak
WGSsell 2
GeneDx Holdings Corp.
Kevin Feeley
CHIEF FINANCIAL OFFICER
$111k
1,280 shares
-6%
32Weak
WGSsell 2
GeneDx Holdings Corp.
Katherine Stueland
CHIEF EXECUTIVE OFFICER
$319k
3,678 shares
-8%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Kevin Feeley sold $438k of WGS | InsiderTell